Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Cash from Investing Activities (2016 - 2026)

Agios Pharmaceuticals (AGIO) has disclosed Cash from Investing Activities for 15 consecutive years, with $141.3 million as the latest value for Q1 2026.

  • For Q1 2026, Cash from Investing Activities rose 25.51% year-over-year to $141.3 million; the TTM value through Mar 2026 reached $405.9 million, up 15.49%, while the annual FY2025 figure was $377.2 million, 3.78% up from the prior year.
  • Cash from Investing Activities hit $141.3 million in Q1 2026 for Agios Pharmaceuticals, up from $90.1 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $250.8 million in Q3 2024 and bottomed at -$49.2 million in Q4 2024.
  • Average Cash from Investing Activities over 5 years is $80.3 million, with a median of $83.0 million recorded in 2022.
  • On a YoY basis, Cash from Investing Activities climbed as much as 537.49% in 2024 and fell as far as 151.47% in 2024.
  • Agios Pharmaceuticals' Cash from Investing Activities stood at $83.0 million in 2022, then increased by 15.14% to $95.5 million in 2023, then plummeted by 151.47% to -$49.2 million in 2024, then skyrocketed by 283.24% to $90.1 million in 2025, then surged by 56.88% to $141.3 million in 2026.
  • According to Business Quant data, Cash from Investing Activities over the past three periods came in at $141.3 million, $90.1 million, and $95.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.